Related Experiment Video
Updated: May 23, 2026
Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
Published on: October 17, 2025
Lapatinib: the evidence for its therapeutic value in metastatic breast cancer
1Core Medical Publishing, Knutsford, UK.
Introduction:
Breast cancer is the most common cancer affecting women. Many patients ultimately progress to metastatic disease and optimal management of this disease remains a significant therapeutic challenge. Lapatinib, a dual tyrosine kinase inhibitor, is in clinical development for treatment of this disease.
Aims:
The objective of this article is to review the published evidence for the treatment of metastatic breast cancer with lapatinib, and assess its therapeutic potential.
Evidence Review:
Most evidence has appeared in meeting abstract reports of phase I and II studies in healthy volunteers and cancer patients. Four studies have included patients with exclusively breast cancer. Complete and partial responses and stable disease has been reported in some patients. Emerging evidence indicates that complete and partial responses can be achieved in some patients with metastatic breast cancer. Lapatinib appears to be well tolerated in cancer patients and the maximum tolerated dose is in the region of 1800 mg/day. In addition, it has been used in combination with other cancer treatments. Five ongoing or planned phase II monotherapy and three phase III combination-therapy studies with lapatinib have been identified.
Outcomes Summary:
The phase I and II studies reported to date have provided safety data and preliminary indications regarding efficacy. There is preliminary evidence that lapatinib can achieve objective response rates of 10-38% in patients with metastatic breast cancer. Patients with tumors overexpressing ErbB1 and/or ErbB2 are likely to benefit from lapatinib treatment.
Insights
Lapatinib shows promise in treating metastatic breast cancer, with objective response rates of 10-38% observed in early studies. This dual tyrosine kinase inhibitor is well-tolerated and may benefit patients with ErbB1/ErbB2 overexpressing tumors.
Area of Science:
- Oncology
- Pharmacology
Background:
- Breast cancer is the most common cancer in women, frequently progressing to metastatic disease.
- Managing metastatic breast cancer presents significant therapeutic challenges.
- Lapatinib, a dual tyrosine kinase inhibitor, is under clinical development for metastatic breast cancer.
Purpose of the Study:
- To review published evidence on lapatinib for metastatic breast cancer treatment.
- To assess the therapeutic potential of lapatinib in this patient population.
Main Methods:
- Review of phase I and II study abstracts, including four studies exclusively on breast cancer patients.
- Evaluation of safety and preliminary efficacy data.
- Identification of ongoing and planned phase II and III studies.
Main Results:
- Lapatinib demonstrated objective response rates of 10-38% in patients with metastatic breast cancer.
- The drug was generally well-tolerated, with a maximum tolerated dose around 1800 mg/day.
- Tumors overexpressing ErbB1 and/or ErbB2 are identified as potential indicators for lapatinib benefit.
Conclusions:
- Phase I and II studies provide initial safety and efficacy data for lapatinib.
- Lapatinib exhibits preliminary efficacy in metastatic breast cancer.
- Targeted therapy with lapatinib may be most effective in patients with specific tumor biomarkers.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:15Drugs that Stabilize Microtubules